Printer Friendly

ADVANCED THERAPEUTIC PRODUCTS TRADES ON NASDAQ BULLETIN BOARD; NEW ATPI STOCK QUOTATION SYSTEM

 ADVANCED THERAPEUTIC PRODUCTS TRADES ON NASDAQ BULLETIN BOARD;
 NEW ATPI STOCK QUOTATION SYSTEM
 SAN ANTONIO, June 5 /PRNewswire/ -- On May 22, 1992, the common stock of Advanced Therapeutic Products, Inc. (NASDAQ "Advanced Tobacco Products") commenced trading on the NASDAQ electronic "Bulletin Board" quotation system under the symbol "ATPI." Previously, the company's common stock had traded on the NASDAQ Weekly Bid and Ask Quotation system from 1984 until May 22, 1992 under the symbol "ATPI."
 Jim Linehan, ATPI's president said, "This change in the company's stock quotation system was required as a result of recently enacted NASDAQ financial standards and not as a result of any change in the company's financial
position." Interested investors and ATPI shareholders can continue to readily trade in the company's stock through stock brokers and the market makers of the company's stock: Paragon Capital, Carr Securities, Datek Securities and Troster-Singer.
 Over the past four years, approximately 10 percent of the company's stock has been traded per year. ATPI has approximately 8,000,000 shares of common stock outstanding.
 The company had considered a reverse stock split to meet the new NASDAQ standards provided NASDAQ approved a temporary waiver to certain assets standards.
 "The change in the company's stock quotation system was required since NASDAQ procedures were unable to grant the requested waiver," Linehan said. Approximately 200 NASDAQ listed companies did not meet the new NASDAQ standards. "ATPI, like many emerging growth companies, was required to seek alternatives," he said.
 In 1987, ATPI sold nicotine technology to a predecessor of Kabi- Pharmacia Therapeutics AB, a Swedish world-wide marketer of pharmaceutical products, including nicotine smoking cessation products: the Nicotrol patch and Nicorette chewing gum. In exchange for its technology, ATPI obtained the right to receive payments from Kabi- Pharmacia's sales of a nicotine inhaler now undergoing clinical trials. The company expects Kabi-Pharmacia to submit a new drug application with the United States Food & Drug Administration in approximately one year. In the event the nicotine inhaler becomes a successful commercial product, ATPI expects substantial royalty revenues from Kabi-Pharmacia.
 -0- 6/5/92
 /CONTACT: Jim Linehan of Advanced Therapeutic Products, 512-490-2292, or Cary Corbin of Dublin-McCarter & Associates, 512-227-0221, for Advanced Therapeutic/
 (ATPI) CO: Advanced Therapeutic Products, Inc. ST: Texas IN: MTC SU:


TQ -- NY046 -- 7504 06/05/92 14:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 5, 1992
Words:381
Previous Article:VOLUNTEER SAVINGS TRANSFERRED TO RESOLUTION TRUST CORPORATION
Next Article:WASTE MANAGEMENT INTERNATIONAL PLC ANNOUNCES AGREEMENT IN SWEDEN
Topics:


Related Articles
ATP ACQUIRES WORLDWIDE RIGHTS TO NEW NICOTINE INHALER TECHNOLOGY
Nicotine Inhaler Launched in Sweden
Advanced Therapeutic Products Announces FDA Clears Nicotine Inhaler Based on ATP Technology for Sale as Prescription Product
Nicotine Inhaler Launched in Austria
Cambridge NeuroScience Announces Nasdaq Delisting.
Life Technologies' Common Stock to Be Delisted From Nasdaq Stock Market Effective With Close of Business February 1, 1999.
Senetek PLC to be Delisted From Nasdaq November 10, 2004.
Cellegy Pharmaceuticals, Inc. Announces Removal of Common Stock from Nasdaq SmallCap Market.
Alfacell Announces Receipt of NASDAQ Panel Decision.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters